Royal Bank of Canada’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Royal Bank of Canada’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-722	Closed	-$3K	–	7879
2023 Q2	$3K	Sell	722 -316	-30%	-$1.16K	﹤0.01%	6822
2023 Q1	$3K	Buy	1,038 +816	+368%	+$2.82K	﹤0.01%	6733
2022 Q4	$0	Buy	222 +137	+161%	+$417	﹤0.01%	7996
2022 Q3	$0	Buy	+85	New	+$387	﹤0.01%	8083
2022 Q1	–	Sell	-1,075	Closed	-$5K	–	8160
2021 Q4	$5K	Sell	1,075 -1,000	-48%	-$6.88K	﹤0.01%	7242
2021 Q3	$16K	Buy	2,075 +269	+15%	+$2.05K	﹤0.01%	6798
2021 Q2	$16K	Buy	1,806 +1,020	+130%	+$9K	﹤0.01%	6689
2021 Q1	$9K	Buy	+786	New	+$12.3K	﹤0.01%	6872

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $875M AUM

Royal Bank of Canada's DBTX Position: Q3 2023 in Review

Royal Bank of Canada sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 722 shares — an estimated $3K sold.

Royal Bank of Canada first reported a position in DBTX in Q1 2021 and held it in 8 quarters. The position peaked at $16K in Q3 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

Royal Bank of Canada reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Royal Bank of Canada sold 722 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3K.
Royal Bank of Canada first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Royal Bank of Canada's Decibel Therapeutics, Inc. Common Stock position peaked at $16K in Q3 2021.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Royal Bank of Canada's 13F filing for Q3 2023, filed 14 Nov 2023.